| Yazarlar (48) |
İlknur Çağlar
Dr. Behcet Uz Children's Hospital, Türkiye |
|
İlker Devrim
Dr. Behcet Uz Children's Hospital, Türkiye |
|
Halil Özdemir
Ankara Üniversitesi, Türkiye |
|
Zümrüt Şahbudak
Ege University Medical School, Türkiye |
|
Gülsüm Sönmez
Çukurova Üniversitesi Tip Fakültesi, Türkiye |
|
Ayse Buyukcam
Hacettepe Üniversitesi, Türkiye |
|
Belgin Gulhan
Ankara Children's Hematology Oncology Training And Research Hospital, Türkiye |
|
Ahu Kara
Dr. Behcet Uz Children's Hospital, Türkiye |
|
Deniz F. Aygun
İstanbul University-Cerrahpaşa Cerrahpaşa Faculty Of Medicine, Türkiye |
|
Nuri Bayram
Dr. Behcet Uz Children's Hospital, Türkiye |
|
Solmaz Celebi
Bursa Uludağ Üniversitesi, Türkiye |
|
Benhur Çetin
Ortopedy Department Of Gaziantep Avukat Cengiz State Hospital, Türkiye |
|
Merve Nepesov
Eskişehir Osmangazi Üniversitesi Tip Fakültesi, Türkiye |
Doç. Dr. Ayşe YILMAZ
Kastamonu Üniversitesi, Türkiye |
|
Eda Kepenekli
Marmara Üniversitesi, Türkiye |
|
Dilek Yilmaz Çiftdogan
İzmir Kâtip Çelebi Üniversitesi, Türkiye |
|
Manolya K. Acar
İstanbul University-Cerrahpaşa Cerrahpaşa Faculty Of Medicine, Türkiye |
|
Burcu Cura Yayla
Gazi University, Faculty Of Medicine, Türkiye |
|
Canan Okumuş
Dokuz Eylül Üniversitesi, Türkiye |
|
Zafer Ecevit
Başkent Üniversitesi, Türkiye |
|
Nevin Hatipoglu
Bak?Rkoy Dr. Sadi Konuk Egitim ve Arast?Rma Hastanesi, Türkiye |
|
Necdet Kuyucu
Mersin Üniversitesi, Türkiye |
|
Muhammed Kosker
Diyarbakir Children's Hospital, Türkiye |
|
Semra Sen
Manisa Celâl Bayar Üniversitesi, Türkiye |
|
Adem Karbuz
Saǧlik Bakanliǧi Okmeydani Eǧitim ve Araştirma Hastanesi, Türkiye |
|
Murat Sutcu
Konya City Hospital, Türkiye |
|
Burcu Bursal Duramaz
Bezmiâlem Vakıf Üniversitesi, Türkiye |
|
Metehan Özen
Acıbadem Mehmet Ali Aydınlar Üniversitesi, Türkiye |
|
Ergin Çiftçi
Ankara Üniversitesi, Türkiye |
|
Derya Alabaz
Çukurova Üniversitesi Tip Fakültesi, Türkiye |
|
Zafer Kurugol
Ege University Medical School, Türkiye |
|
Ateş Kara
Hacettepe Üniversitesi, Türkiye |
|
Saliha Kanik
Ankara Children's Hematology Oncology Training And Research Hospital, Türkiye |
|
Omer Kilic
Eskişehir Osmangazi Üniversitesi Tip Fakültesi, Türkiye |
|
Selim Oncel
Kocaeli Üniversitesi, Türkiye |
|
Ayper Somer
İstanbul University-Cerrahpaşa Cerrahpaşa Faculty Of Medicine, Türkiye |
|
Anil Tapisiz
Gazi University, Faculty Of Medicine, Türkiye |
|
Nursen Belet
Dokuz Eylül Üniversitesi, Türkiye |
|
Özge Metin Akcan
Konya City Hospital, Türkiye |
|
Özden Türel
Bezmiâlem Vakıf Üniversitesi, Türkiye |
|
Aslinur Ozkaya
Ankara Children's Hematology Oncology Training And Research Hospital, Türkiye |
|
Hasan Tezer
Gazi University, Faculty Of Medicine, Türkiye |
|
Ali Bulent Cengiz
Hacettepe Üniversitesi, Türkiye |
|
Erdal İnce
Ankara Üniversitesi, Türkiye |
|
Yıldız Camcioglu
İstanbul University-Cerrahpaşa Cerrahpaşa Faculty Of Medicine, Türkiye |
|
Emine Kocabas
Çukurova Üniversitesi Tip Fakültesi, Türkiye |
|
Emin S. Arisoy
Kocaeli Üniversitesi, Türkiye |
|
Nuran Salman
İstanbul University-Cerrahpaşa Cerrahpaşa Faculty Of Medicine, Türkiye |
| Özet |
| Objectives: The aim of this point prevalence survey was to evaluate the consumption, indications and strategies of antifungal therapy in the paediatric population in Turkey. Methods: A point prevalence study was performed at 25 hospitals. In addition to general data on paediatric units of the institutes, the generic name and indication of antifungal drugs, the presence of fungal isolation and susceptibility patterns, and the presence of galactomannan test and high-resolution computed tomography (HRCT) results were reviewed. Results: A total of 3338 hospitalised patients were evaluated. The number of antifungal drugs prescribed was 314 in 301 patients (9.0%). Antifungal drugs were mostly prescribed in paediatric haematology and oncology (PHO) units (35.2%), followed by neonatal ICUs (NICUs) (19.6%), paediatric services (18.3%), paediatric ICUs (PICUs) (14.6%) and haematopoietic stem cell transplantation (HSCT) units (7.3%). Antifungals were used for prophylaxis in 147 patients (48.8%) and for treatment in 154 patients (50.0%). The antifungal treatment strategy in 154 patients was empirical in 77 (50.0%), diagnostic-driven in 29 (18.8%) and targeted in 48 (31.2%). At the point of decision-making for diagnostic-driven antifungal therapy in 29 patients, HRCT had not been performed in 1 patient (3.4%) and galactomannan test results were not available in 12 patients (41.4%). Thirteen patients (8.4%) were receiving eight different antifungal combination therapies. Conclusion: The majority of antifungal drugs for treatment and prophylaxis were prescribed in PHO and HSCT units (42.5%), followed by ICUs. Thus, antifungal stewardship programmes should mainly focus on these patients within the availability of diagnostic tests of each hospital. |
| Anahtar Kelimeler |
| Antifungals | Indications | Paediatric tertiary hospital | Point prevalence survey |
| Makale Türü | Özgün Makale |
| Makale Alt Türü | SCOPUS dergilerinde yayınlanan tam makale |
| Dergi Adı | Journal of Global Antimicrobial Resistance |
| Dergi ISSN | 2213-7165 Wos Dergi Scopus Dergi |
| Makale Dili | İngilizce |
| Basım Tarihi | 12-2018 |
| Cilt No | 15 |
| Sayı | 1 |
| Sayfalar | 232 / 238 |
| Doi Numarası | 10.1016/j.jgar.2018.08.007 |
| Atıf Sayıları | |
| SCOPUS | 4 |
